MARA gives pharma & investors independent Market Access Risk Ratings (A++ to C) to avoid payer surprises early.
MARA Rating | Market Access Risk Assessment is a leading provider of independent market access risk ratings for the pharmaceutical industry and investors. Based in Basel, Basel 04050, CH, MARA Rating | Market Access Risk Assessment delivers unbiased assessments that empower pharmaceutical teams with precise insights into their drugs' market access potential, benchmarked against competitors through a proprietary 10-domain HTA framework.
Trusted by numerous top pharmaceutical companies, MARA Rating | Market Access Risk Assessment transforms qualitative intuition into data-driven insights, offering A++-to-C scores that forecast reimbursement outcomes with remarkable precision. The company specializes in a range of services, including evidence synthesis, pricing strategy, payer advisory services, and health technology assessment, enabling decision-makers to de-risk multi-billion-dollar launch strategies.
MARA Rating | Market Access Risk Assessment's commitment to providing accurate and actionable intelligence makes it an invaluable partner for pharmaceutical companies seeking to optimize their market access strategies and secure successful reimbursement outcomes. We invite the manager of MARA Rating | Market Access Risk Assessment to create a customized and exclusive company showcase and product listing on our platform to further enhance their market presence.
MARA Rating | Market Access Risk Assessment est un fournisseur de premier plan d'évaluations indépendantes des risques d'accès au marché pour l'industrie pharmaceutique et les investisseurs. Basée à Basel, Basel 04050, CH, MARA Rating | Market Access Risk Assessment fournit des évaluations impartiales qui permettent aux équipes pharmaceutiques d'obtenir des informations précises sur le potentiel d'accès au marché de leurs médicaments, par rapport à leurs concurrents grâce à un cadre HTA exclusif à 10 domaines.
Approuvée par de nombreuses grandes sociétés pharmaceutiques, MARA Rating | Market Access Risk Assessment transforme l'intuition qualitative en informations basées sur les données, offrant des scores de A++ à C qui prévoient les résultats de remboursement avec une précision remarquable. La société est spécialisée dans une gamme de services, notamment la synthèse des preuves, la stratégie de prix, les services de conseil aux payeurs et l'évaluation des technologies de la santé, permettant aux décideurs de réduire les risques liés aux stratégies de lancement de plusieurs milliards de dollars.
L'engagement de MARA Rating | Market Access Risk Assessment à fournir des informations précises et exploitables en fait un partenaire précieux pour les sociétés pharmaceutiques qui cherchent à optimiser leurs stratégies d'accès au marché et à obtenir des résultats de remboursement positifs. Nous invitons le responsable de MARA Rating | Market Access Risk Assessment à créer une présentation d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme afin d'améliorer davantage leur présence sur le marché.
Compare MARA Rating | Market Access Risk Assessment with 3 companies in Pharmaceutical-Manufacturing
| Comparison Field |
MARA Rating | Market Acce...Main Company |
SKC Beratungsgesells...View Profile |
ConnectHEORView Profile |
PRECISIONheorView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2005 | 2020 | |
|
Company Size
|
— | 11-50 | 11-50 | 51-200 |
|
City
|
Basel, Basel | Hannover, Niedersachsen | London, England | New York, New York |
|
Country
|
Switzerland | Germany | United Kingdom | United States |
|
Skills & Keywords
Comparing with main company
|
26 Total Skills
Market Access Risk Assessment
Pharmaceutical Manufacturing
HTA Framework
Reimbursement Outcomes
Pricing Strategy
Payer Advisory
Drug Valuation
Evidence Synthesis
Payer Advisory Services
Launch Sequence Planning
Health Technology Assessment (HTA)
Health Economics & Outcomes Research
Deal Due Diligence
Comparator Landscape Analysis
Risk Rating Methodologies
Real-World Evidence Insights
Payer Behaviour Modelling
Data-Driven Life-Science Insights
Decision Intelligence for Pharma
Portfolio Benchmarking
Strategic Consulting
Market Access Risk Ratings
Pricing & Reimbursement Analytics
Drug Valuation Support
Reimbursement Strategy
Biopharma Investment Intelligence
|
9 Total
9 Unique
Unique Skills:
ATMPs
Digital Health
Dossier Preparation
Full Market Access Support
Gene Therapy
Market Access Strategy
+3
|
17 Total
17 Unique
Unique Skills:
Consultancy
Data Analysis
Data Analytics
Decision Modelling
Health Economic Modelling
Health Economics
+11
|
7 Total
7 Unique
Unique Skills:
Health Technology Assessment
HTA Preparation
Mixed Methods Observational Research
Predictive Modeling
Real World Evidence
RWE
+1
|
Other organizations in the same industry
This company is also known as